CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
CA2430010A1
(fr)
|
2000-11-30 |
2002-06-06 |
University Of Florida |
Traitements de troubles neurogenetiques, de troubles du controle des impulsions, et cicatrisation des lesions
|
PT1368349E
(pt)
*
|
2001-02-24 |
2007-04-30 |
Boehringer Ingelheim Pharma |
Derivados de xantina, sua preparação e sua utilização como medicamento
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
WO2002080936A1
(fr)
*
|
2001-04-04 |
2002-10-17 |
Ortho Mcneil Pharmaceutical, Inc. |
Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
|
CA2444481A1
(fr)
*
|
2001-04-11 |
2002-10-24 |
Bristol-Myers Squibb Company |
Complexes acides amines de glucocides c-aryle pour le traitement du diabete et procede correspondant
|
WO2003020737A1
(fr)
*
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1550668A4
(fr)
*
|
2002-10-04 |
2008-10-01 |
Kissei Pharmaceutical |
Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
BR0317929A
(pt)
*
|
2003-01-03 |
2006-04-11 |
Bristol Myers Squibb Co |
métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
|
EP1457206A1
(fr)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
|
US7202350B2
(en)
|
2003-03-14 |
2007-04-10 |
Astellas Pharma Inc. |
C-glycoside derivatives and salts thereof
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
CA2549017A1
(fr)
*
|
2003-08-01 |
2005-02-10 |
Mona Patel |
Indazoles-o-glucosides substitues
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
CA2549025A1
(fr)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Indole-o-glucosides substitues
|
AR045173A1
(es)
*
|
2003-08-01 |
2005-10-19 |
Tanabe Seiyaku Co |
Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
|
EA009768B1
(ru)
*
|
2003-08-01 |
2008-04-28 |
Янссен Фармацевтика Нв |
Замещенные конденсированные гетероциклические с-гликозиды
|
AR048377A1
(es)
*
|
2003-08-01 |
2006-04-26 |
Janssen Pharmaceutica Nv |
Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US7732596B2
(en)
*
|
2004-03-04 |
2010-06-08 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
EA011158B1
(ru)
|
2004-03-16 |
2009-02-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
ATE493973T1
(de)
|
2004-06-04 |
2011-01-15 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
WO2006010557A1
(fr)
*
|
2004-07-27 |
2006-02-02 |
Boehringer Ingelheim International Gmbh |
Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
MX2007003785A
(es)
*
|
2004-09-29 |
2007-07-12 |
Kissei Pharmaceutical |
Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
JP4944034B2
(ja)
*
|
2004-10-13 |
2012-05-30 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Ptp1b発現のアンチセンス調節
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7687469B2
(en)
*
|
2004-12-16 |
2010-03-30 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637869A
(en)
*
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
MY147375A
(en)
*
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
ES2319461T3
(es)
*
|
2005-02-10 |
2009-05-07 |
Bristol-Myers Squibb Company |
Dihidroquinazolinonas como moduladores de 5ht.
|
ATE445608T1
(de)
*
|
2005-02-23 |
2009-10-15 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
|
WO2006108842A1
(fr)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(fr)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
JP5128474B2
(ja)
*
|
2005-07-27 |
2013-01-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換((ヘテロ)シクロアルキルエチニル−ベンジル)−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
|
WO2007016353A2
(fr)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
WO2007025943A2
(fr)
*
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
|
US8507450B2
(en)
*
|
2005-09-08 |
2013-08-13 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
WO2007074884A1
(fr)
*
|
2005-12-28 |
2007-07-05 |
Takeda Pharmaceutical Company Limited |
Agent thérapeutique pour traiter le diabète
|
KR20080102395A
(ko)
|
2006-02-15 |
2008-11-25 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
US20090176717A1
(en)
*
|
2006-06-01 |
2009-07-09 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
JP5384343B2
(ja)
|
2006-08-15 |
2014-01-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、sglt阻害剤としてのそれらの使用及びそれらの製造方法
|
EP2066344B2
(fr)
*
|
2006-09-07 |
2016-06-29 |
GlaxoSmithKline Biologicals S.A. |
Vaccin combiné du virus de poliomyelite inactivé
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
EP2072522A4
(fr)
*
|
2006-10-13 |
2010-01-06 |
Chugai Pharmaceutical Co Ltd |
Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
|
CA2667550A1
(fr)
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
Forme cristalline du 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)- tetrahydrofuran-3-yloxy)benzyl]-benzene, procede pour la preparation de celle-ci et utilisation de celle-cipour preparer des medicaments
|
US7666845B2
(en)
*
|
2006-12-04 |
2010-02-23 |
Janssen Pharmaceutica N.V. |
Compounds having inhibitory activity against sodium-dependent glucose transporter
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
EA015835B1
(ru)
|
2006-12-06 |
2011-12-30 |
Смитклайн Бичем Корпорейшн |
Производные 4-окса(тиа)метилпиперидина и их применение в качестве противодиабетических средств
|
CA2673498C
(fr)
*
|
2006-12-21 |
2012-04-24 |
Astellas Pharma Inc. |
Procede de fabrication d'un derive de c-glycoside et intermediaire de synthese de celui-ci
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
PE20090185A1
(es)
*
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CA2688161C
(fr)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
KR101663324B1
(ko)
*
|
2007-07-26 |
2016-10-06 |
렉시컨 파마슈티컬스 인코퍼레이티드 |
나트륨 글루코스 공-전달체 2 억제제의 제조에 유용한 방법 및 화합물
|
CL2008002427A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
CL2008002425A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
|
US20110112069A1
(en)
*
|
2007-08-17 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
PL2187742T3
(pl)
*
|
2007-08-23 |
2018-06-29 |
Theracos Sub, Llc |
Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
|
HUE035130T2
(en)
*
|
2007-09-10 |
2018-05-02 |
Janssen Pharmaceutica Nv |
A method for preparing compounds useful as SGLT inhibitors
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
WO2009068617A1
(fr)
*
|
2007-11-30 |
2009-06-04 |
Boehringer Ingelheim International Gmbh |
Dérivés de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
MX2010007426A
(es)
*
|
2008-01-31 |
2010-08-18 |
Astellas Pharma Inc |
Composiciones farmaceuticas para tratar trastorno del higado graso.
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
US8603989B2
(en)
*
|
2008-05-22 |
2013-12-10 |
Bristol-Myers Squibb Company |
Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
|
CA2725047A1
(fr)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Procede de traitement de l'hyperuricemie a l'aide d'un inhibiteur de sglt2 et composition le contenant
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
TWI523652B
(zh)
*
|
2008-07-15 |
2016-03-01 |
泰瑞克公司 |
氘化苄基苯衍生物及使用方法
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
WO2010018217A2
(fr)
*
|
2008-08-15 |
2010-02-18 |
Boehringer Ingelheim International Gmbh |
Composés organiques pour la cicatrisation de lésion
|
AR073118A1
(es)
*
|
2008-08-22 |
2010-10-13 |
Theracos Inc |
Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
|
BRPI0918841B8
(pt)
*
|
2008-08-28 |
2021-05-25 |
Pfizer |
derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
|
WO2010026214A1
(fr)
|
2008-09-08 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
JP2012502950A
(ja)
*
|
2008-09-19 |
2012-02-02 |
ノバルティス アーゲー |
グリコシド誘導体およびその使用
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
WO2010045656A2
(fr)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Nouvelles formes posologiques d'inhibiteur sglt2
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
CN102316875A
(zh)
|
2009-02-13 |
2012-01-11 |
贝林格尔.英格海姆国际有限公司 |
用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
AU2010212867B2
(en)
|
2009-02-13 |
2013-05-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
|
NZ594024A
(en)
*
|
2009-02-13 |
2013-08-30 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
TWI460187B
(zh)
*
|
2009-02-23 |
2014-11-11 |
大正製藥股份有限公司 |
4-異丙基苯基葡萄糖醇化合物
|
EP2226076A1
(fr)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Support d'enregistrement thermosensible et procédé d'enregistrement
|
JP5542196B2
(ja)
*
|
2009-03-31 |
2014-07-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1−複素環−1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びpde9aモジュレーターとしてのそれらの使用
|
CN102639125A
(zh)
*
|
2009-05-27 |
2012-08-15 |
百时美施贵宝公司 |
使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
JP5658751B2
(ja)
|
2009-07-10 |
2015-01-28 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap |
1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
JP5758900B2
(ja)
*
|
2009-09-30 |
2015-08-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
|
EP2483286B1
(fr)
*
|
2009-09-30 |
2016-07-13 |
Boehringer Ingelheim International GmbH |
Procédé de préparation d'une forme cristalline de 1-chloro-4-( -d-glucopyranos-1-yl)-2-[4-((s)-tétrahydrofuran-3-yloxy)-benzyl]-benzène
|
US10610489B2
(en)
*
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
DK2488515T3
(en)
*
|
2009-10-14 |
2017-02-27 |
Janssen Pharmaceutica Nv |
PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
SI2496583T1
(sl)
|
2009-11-02 |
2015-02-27 |
Pfizer Inc. |
Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
|
PL2498758T3
(pl)
|
2009-11-13 |
2019-02-28 |
Astrazeneca Ab |
Formulacje tabletek dwuwarstwowych
|
MX2012005365A
(es)
|
2009-11-13 |
2012-05-29 |
Bristol Myers Squibb Co |
Formulaciones de tableta de liberacion inmediata.
|
EP2501685A1
(fr)
|
2009-11-16 |
2012-09-26 |
Mellitech |
Dérivés de [1,5]-diazocine
|
EP3646859A1
(fr)
|
2009-11-27 |
2020-05-06 |
Boehringer Ingelheim International GmbH |
Traitement de patients diabétiques génotypés avec des inhibiteurs de dpp-iv tels que la linagliptine
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
EP2552442A1
(fr)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Composition pharmaceutique comprenant un inhibiteur sglt2 et un agoniste ppar-gamma, utilisations correspondantes
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
US20130052266A1
(en)
|
2010-05-11 |
2013-02-28 |
Mitsubishi Tanabe Pharma Corporation |
TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
|
MX339570B
(es)
|
2010-05-11 |
2016-05-31 |
Janssen Pharmaceutica Nv |
Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
BR112012032579B1
(pt)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
|
PE20130602A1
(es)
|
2010-08-12 |
2013-05-25 |
Boehringer Ingelheim Int |
Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
|
WO2012025857A1
(fr)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
|
EP2611442B1
(fr)
|
2010-09-03 |
2018-07-04 |
Bristol-Myers Squibb Company |
Formulations de médicament au moyen d'antioxydants hydrosolubles
|
US8921328B2
(en)
|
2010-09-14 |
2014-12-30 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(fr)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2012106303A1
(fr)
|
2011-02-01 |
2012-08-09 |
Bristol-Myers Squibb Company |
Formulations pharmaceutiques comprenant un composé amine
|
US20130035281A1
(en)
*
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
CN102643256B
(zh)
*
|
2011-02-18 |
2014-12-24 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
SI2697218T1
(sl)
|
2011-04-13 |
2016-07-29 |
Janssen Pharmaceutica Nv |
Postopek za pripravo spojin, koristnih kot zaviralci sglt2
|
JP2014512399A
(ja)
*
|
2011-04-25 |
2014-05-22 |
ベイジン・プレリュード・ファーム・サイ・アンド・テック・カンパニー・リミテッド |
ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
AP3308A
(en)
*
|
2011-05-26 |
2015-06-30 |
Tfchem |
Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
|
WO2012163990A1
(fr)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Inhibiteurs de sglt-2 pour traiter des troubles métaboliques chez des patients traités avec des agents neuroleptiques
|
US9480755B2
(en)
*
|
2011-06-03 |
2016-11-01 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
EP2529742B1
(fr)
|
2011-06-03 |
2013-11-20 |
ratiopharm GmbH |
Composition pharmaceutique comportant de la dapagliflozine et cyclodextrine
|
US9562029B2
(en)
|
2011-06-25 |
2017-02-07 |
Xuanzhu Pharma Co., Ltd. |
C-glycoside derivatives
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HUE043540T2
(hu)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
|
JP2014530186A
(ja)
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
BR112014010574A2
(pt)
*
|
2011-10-31 |
2017-05-02 |
Scinopharm Taiwan Ltd |
formas cristalinas e não cristalinas de inibidores sglt2
|
EP2597090A1
(fr)
*
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Hydrate de dapagliflozine cristalline
|
WO2013096926A1
(fr)
|
2011-12-22 |
2013-06-27 |
Glycomimetics, Inc. |
Composés antagonistes de la sélectine e, compositions et méthodes d'utilisation
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP3685839A1
(fr)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
CN103450214B
(zh)
*
|
2012-05-29 |
2016-04-06 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(fr)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
BR112015004012A2
(pt)
|
2012-08-30 |
2017-07-04 |
Taisho Pharmaceutical Co Ltd |
combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
|
LT2928476T
(lt)
|
2012-12-07 |
2018-05-25 |
Glycomimetics, Inc. |
Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(fr)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Composition pour le traitement de pathologies hyperglycémiques
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
EP3466431B1
(fr)
|
2013-03-14 |
2023-11-15 |
MSD International GmbH |
Formes crystallins et modes preparatoires pour la manufacture des inhibiteurs de sglt2
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(fr)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
CN113181161A
(zh)
|
2013-04-18 |
2021-07-30 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
WO2014178040A1
(fr)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-cristaux de dapagliflozine
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
US20160214953A1
(en)
|
2013-09-23 |
2016-07-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of dapagliflozin
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
US20160237054A1
(en)
*
|
2013-09-27 |
2016-08-18 |
Sun Pharmaceutical Industries Limited |
Process for the purification of dapagliflozin
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
WO2015063726A1
(fr)
|
2013-10-31 |
2015-05-07 |
Ranbaxy Laboratories Limited |
Procédé de préparation de 4-bromo-1-chloro-2-(4-éthoxybenzyl)benzène
|
CN111494357A
(zh)
|
2013-12-17 |
2020-08-07 |
勃林格殷格翰动物保健有限公司 |
猫科动物中代谢紊乱的治疗
|
WO2015101916A1
(fr)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Procédé pour la préparation d'empagliflozin
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
MX2016009421A
(es)
|
2014-01-23 |
2016-09-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabolicos en animales caninos.
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(fr)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
US20170056365A1
(en)
|
2014-02-28 |
2017-03-02 |
Sun Pharmaceutical Industries Limited |
Dapagliflozin compositions
|
IN2014CH01141A
(fr)
*
|
2014-03-06 |
2015-09-11 |
Msn Lab Private Ltd |
|
HUE050095T2
(hu)
|
2014-04-01 |
2020-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Anyagcsere-rendellenességek kezelése lófélékben
|
CN105001213B
(zh)
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP3142661B1
(fr)
*
|
2014-05-16 |
2021-10-06 |
Astrazeneca AB |
Méthode de suppression de la sécrétion de glucagon d'un inhibiteur de sglt2
|
EP2944311A1
(fr)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
|
WO2015198227A1
(fr)
|
2014-06-23 |
2015-12-30 |
Sun Pharmaceutical Industries Limited |
Co-cristal de dapagliflozin et d'acide citrique
|
CA2961148A1
(fr)
|
2014-09-25 |
2016-03-31 |
Astrazeneca Ab |
Utilisation d'une combinaison d'acide gras omega 3 et d'un inhibiteur desglt-2 destinee au traitement de maladie du foie non liee a l'alcool
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
SI3227310T1
(sl)
|
2014-12-03 |
2019-11-29 |
Glycomimetics Inc |
Heterobifunkcionalni inhibitorji e-selektinov in receptorjev kemokina CXCR4
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
WO2016128995A1
(fr)
|
2015-02-09 |
2016-08-18 |
Indoco Remedies Limited |
Procédé de préparation de composés inhibiteurs de sglt
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
WO2016161995A1
(fr)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Formes solides de dapagliflozine amorphe
|
WO2016178148A1
(fr)
*
|
2015-05-05 |
2016-11-10 |
Glenmark Pharmaceuticals Limited |
Procédé de préparation de dapagliflozine
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
ES2896101T3
(es)
|
2015-09-15 |
2022-02-23 |
Laurus Labs Ltd |
Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのsglt−2阻害剤
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
AU2017205545B2
(en)
*
|
2016-01-04 |
2019-11-21 |
Je Il Pharmaceutical Co., Ltd. |
C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
|
WO2017118945A1
(fr)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Prémélange de dapagliflozine et son procédé de préparation
|
WO2017127422A1
(fr)
|
2016-01-22 |
2017-07-27 |
Glycomimetics, Inc. |
Inhibiteurs glycomimétiques des lectines pa-il et pa-iil
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
BR112018069782A2
(pt)
|
2016-03-31 |
2019-01-29 |
Lupin Ltd |
composição farmacêutica de dapagliflozina
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
BR112018071991A2
(pt)
*
|
2016-05-24 |
2019-02-12 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
forma de cristal da dapaglifozina e método para a preparação e uso da mesma
|
WO2017203229A1
(fr)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Prémélanges de dapagliflozine
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
WO2018002673A1
(fr)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
|
JP2019524791A
(ja)
|
2016-08-08 |
2019-09-05 |
グリコミメティクス, インコーポレイテッド |
E−セレクチンの阻害剤もしくはcxcr4の阻害剤との、またはe−セレクチンおよびcxcr4両方のヘテロ二機能性阻害剤とのt細胞チェックポイント阻害剤の組み合わせ
|
US11427555B2
(en)
*
|
2016-08-09 |
2022-08-30 |
Laurus Labs Limited |
Processes for preparation of dapagliflozin or its solvates or co-crystals thereof
|
WO2018029264A1
(fr)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Procédé de préparation de dapagliflozine et de ses intermédiaires
|
KR20240046288A
(ko)
|
2016-10-07 |
2024-04-08 |
글리코미메틱스, 인크. |
매우 강력한 다량체성 e-셀렉틴 길항물질
|
WO2018073154A1
(fr)
|
2016-10-19 |
2018-04-26 |
Boehringer Ingelheim International Gmbh |
Combinaisons comprenant un inhibiteur de ssao/vap-1 et un inhibiteur de sglt2, leurs utilisations
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(fr)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Procédé de préparation de dapagliflozine
|
CA3054605A1
(fr)
|
2017-03-15 |
2018-09-20 |
Glycomimetics, Inc. |
Derives de galactopyranosyle-cyclohexyle utilises en tant qu'antagonistes d'e-selectine
|
WO2018167589A1
(fr)
|
2017-03-16 |
2018-09-20 |
Inventia Healthcare Private Limited |
Composition pharmaceutique comprenant de la dapagliflozine
|
CN110996951A
(zh)
|
2017-04-03 |
2020-04-10 |
科赫罗斯生物科学股份有限公司 |
治疗进行性核上性麻痹的PPARγ激动剂
|
WO2018207111A1
(fr)
|
2017-05-09 |
2018-11-15 |
Piramal Enterprises Limited |
Procédé de préparation d'inhibiteurs de sglt2 et de ses intermédiaires
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
WO2019108750A1
(fr)
|
2017-11-30 |
2019-06-06 |
Glycomimetics, Inc. |
Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
|
JP7304863B2
(ja)
|
2017-12-29 |
2023-07-07 |
グリコミメティクス, インコーポレイテッド |
E-セレクチンおよびガレクチン-3のヘテロ二機能性阻害剤
|
US11707474B2
(en)
|
2018-03-05 |
2023-07-25 |
Glycomimetics, Inc. |
Methods for treating acute myeloid leukemia and related conditions
|
EP3781166A1
(fr)
|
2018-04-17 |
2021-02-24 |
Boehringer Ingelheim International GmbH |
Composition pharmaceutique, méthodes de traitement et utilisations associées
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(fr)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
Nouveau procédé de préparation d'inhibiteurs de sglt-2
|
KR20200005320A
(ko)
|
2018-07-06 |
2020-01-15 |
한미약품 주식회사 |
무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
|
EA202190226A1
(ru)
*
|
2018-07-19 |
2021-06-16 |
Астразенека Аб |
СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
|
WO2020039394A1
(fr)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
Nouvelles combinaisons de médicaments
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
US10973836B2
(en)
|
2019-08-30 |
2021-04-13 |
Astrazeneca Ab |
Methods of treating heart failure with reduced ejection fraction
|
JP7441946B2
(ja)
|
2019-11-28 |
2024-03-01 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
非ヒト動物の乾乳におけるsglt-2阻害剤の使用
|
CA3167531A1
(fr)
|
2020-02-17 |
2021-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prevention et/ou le traitement de maladies cardiaques chez les felins
|
CA3169665A1
(fr)
|
2020-02-21 |
2021-08-26 |
Zaklady Farmaceutyczne Polpharma S.A. |
Composition pharmaceutique comprenant de la dapagliflozine
|
WO2021176096A1
(fr)
|
2020-03-05 |
2021-09-10 |
Krka, D.D., Novo Mesto |
Composition pharmaceutique comprenant un inhibiteur du sglt2
|
MX2022010748A
(es)
|
2020-03-06 |
2022-09-23 |
Vertex Pharma |
Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
|
JP2023523596A
(ja)
|
2020-04-22 |
2023-06-06 |
バイエル アクチェンゲゼルシャフト |
心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
WO2021245253A1
(fr)
|
2020-06-05 |
2021-12-09 |
Krka, D.D., Novo Mesto |
Préparation de dapagliflozine amorphe très pure
|
WO2021260617A1
(fr)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
|
MX2023000276A
(es)
|
2020-07-10 |
2023-02-09 |
Astrazeneca Ab |
Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica.
|
TW202220672A
(zh)
|
2020-07-27 |
2022-06-01 |
瑞典商阿斯特捷利康公司 |
用達格列淨治療慢性腎臟病之方法
|
WO2022051316A1
(fr)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
|
EP4206212A1
(fr)
|
2020-09-30 |
2023-07-05 |
Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. |
Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
WO2022119543A1
(fr)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
|
WO2022208172A1
(fr)
|
2021-04-01 |
2022-10-06 |
Astrazeneca Uk Limited |
Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine
|
EP4079296A1
(fr)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
KR20240041966A
(ko)
|
2021-07-28 |
2024-04-01 |
베링거잉겔하임베트메디카게엠베하 |
고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
WO2023006747A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies rénales chez des mammifères non humains
|
WO2023006745A1
(fr)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(fr)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Combinaison d'obicetrapib et d'inhibiteur de sglt2
|
EP4212150A1
(fr)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2023237512A1
(fr)
|
2022-06-07 |
2023-12-14 |
Astrazeneca Ab |
Combinaisons de modulateurs de rxfp1 et d'inhibiteurs de sglt2
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|